XenTech
French translational oncology CRO built around patient-derived xenograft models, with drug response and biomarker discovery services.
7 contract research organizations in our directory list PDX Models as a capability, across 4 countries. 0 report GLP capability and 0 report AAALAC accreditation. Compare their species, services and accreditations below, and contact labs directly from their profiles.
Patient-derived xenograft (PDX) models are created by implanting tumor tissue from patients directly into immunodeficient mice. Because they are passaged as tissue rather than grown as cell lines, they keep more of the original tumor histology, heterogeneity and genetics, which makes them a better predictor of clinical response than many cell-line xenografts.
Most CROs offering PDX work hold banks of characterized models with genomic, transcriptomic and treatment-history data, so sponsors can choose models carrying a specific mutation or resistance profile. Population-style "mouse clinical trials" test a drug across many models, often with one or a few animals per model, to see which tumor types respond and why.
Two limits are worth planning for. Human stroma is gradually replaced by mouse stroma, and without a functional immune system, immuno-oncology agents need humanized-mouse PDX or syngeneic models instead. Growth rates also vary widely between models, so lead time to study start depends on which ones you choose.
Showing 7 CROs. Order rotates daily so no lab is permanently listed first.
French translational oncology CRO built around patient-derived xenograft models, with drug response and biomarker discovery services.
Kentucky CRO developing immunodeficient rat and mouse models, offering xenograft efficacy and safety studies in larger rodent hosts.
Berlin oncology CRO with a large collection of patient-derived xenograft models for in vivo efficacy and biomarker studies.
San Diego oncology CRO offering patient-derived and orthotopic tumor models for in vivo efficacy and translational studies.
Chinese provider of genetically engineered mouse models with in vivo pharmacology services across oncology, immunology and metabolic disease.
Shanghai oncology CRO with patient-derived xenograft and other tumor models for efficacy studies.
Nonprofit mouse genetics institute offering contract in vivo pharmacology using its own strains and humanized and PDX models across oncology, neuroscience, metabolism and immunology.